

3050 Spruce Street, St. Louis, MO 63103 USA
Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757
email: techservice@sial.com sigma-aldrich.com

# **Product Information**

RAF1 (EE) (306-end), Active human, recombinant GST-tagged, expressed in *Sf*9 cells

Catalog Number **R1656**Lot Number 019K1593
Storage Temperature –70 °C

#### **Product Description**

RAF1 is a MAP kinase kinase kinase (MAP3K), which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. The activated RAF1 can phosphorylate and activate the dual specificity protein kinases MEK1 and MEK2, which in turn phosphorylate and activate the serine/threonine specific protein kinases ERK1 and ERK2. Activated ERKs are pleiotropic effectors of cell physiology and play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation, and cell migration.<sup>2</sup>

This recombinant product was expressed by baculovirus in *Sf*9 insect cells using an N-terminal GST-tag. The gene accession number is NM 002880. It is supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.

Molecular mass: ~63 kDa

Purity: ≥70% (SDS-PAGE, see Figure 1)

Specific Activity: 5,100–6,900 nmole/min/mg (see Figure 2)


## **Precautions and Disclaimer**

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.


# Storage/Stability

The product ships on dry ice and storage at -70 °C is recommended. After opening, aliquot into smaller quantities and store at -70 °C. Avoid repeated handling and multiple freeze/thaw cycles.

**Figure 1.**SDS-PAGE Gel of Lot Number 019K1593: >85% (densitometry)



**Figure 2.**Specific Activity of Lot Number 019K1593: 6,000 nmole/min/mg



#### **Procedure**

## **Preparation Instructions**

Kinase Assay Buffer – 25 mM MOPS, pH 7.2, 12.5 mM glycerol 2-phosphate, 25 mM MgCl<sub>2</sub>, 5 mM EGTA, and 2 mM EDTA. Just prior to use, add DTT to a final concentration of 0.25 mM.

Kinase Dilution Buffer – Dilute the Kinase Assay Buffer 5-fold with a 50 ng/µl BSA solution.

Kinase Solution – Dilute the Active RAF1  $(0.1 \mu g/\mu l)$  with Kinase Dilution Buffer to the desired concentration. Note: The lot-specific specific activity plot may be used as a guideline (see Figure 2). It is recommended that the researcher perform a serial dilution of Active RAF1 kinase for optimal results.

10 mM ATP Stock Solution – Dissolve 55 mg of ATP in 10 ml of Kinase Assay Buffer. Store in 200  $\mu$ l aliquots at –20 °C.

 $\gamma$ -<sup>32</sup>P-ATP Assay Cocktail (250 μM) – Combine 5.75 ml of Kinase Assay Buffer, 150 μl of 10 mM ATP Stock Solution, 100 μl of  $\gamma$ -<sup>32</sup>P-ATP (1 mCi/100 μl). Store in 1 ml aliquots at –20 °C.

Substrate Solutions – Inactive MEK1 (0.2  $\mu$ g/ $\mu$ l); Inactive ERK1 (0.2  $\mu$ g/ $\mu$ l); Myelin Basic Protein (MBP) diluted in water at a final concentration of 1mg/ml.

1% phosphoric acid solution – Dilute 10 ml of concentrated phosphoric acid to a final volume of 1 L with water.

#### Kinase Assay

This assay involves the use of the <sup>32</sup>P radioisotope. All institutional guidelines regarding the use of radioisotopes should be followed.

- 1. Thaw the Active RAF1, Kinase Assay Buffer, Inactive ERK1, Inactive MEK1, and Kinase Dilution Buffer on ice. The  $\gamma$ -32P-ATP Assay Cocktail may be thawed at room temperature.
- 2. In a pre-cooled microcentrifuge tube, prepare an activation mixture with a final volume of 20 ul:

10 μl of Kinase Solution

2 μl of inactive MEK1 (0.2 μg/μl)

3  $\mu$ l of inactive ERK1 (0.2  $\mu$ g/ $\mu$ l)

5 μl of Kinase Dilution Buffer

- 3. Start the activation reaction by adding 5  $\mu$ l of 250  $\mu$ M ATP and incubate in a water bath at 30 °C for 25 minutes.
- 4. In a microcentrifuge tube, add the following solutions to a volume of 20 μl on ice:

5 μl of the activated mixture (step 3)

5 μl of MBP Substrate Solution (4 °C)

10 μl of cold water (4 °C)

5. Set up a blank control as outlined in step 4, substituting 5  $\mu$ l of cold water (4 °C) for the Substrate Solution.

- 6. Initiate each reaction with the addition of 5  $\mu$ l of the  $\gamma$ - $^{32}$ P-ATP Assay Cocktail, bringing the final reaction volume to 25  $\mu$ l. Incubate the mixture in a water bath at 30 °C for 15 minutes.
- After the 15 minute incubation, stop the reaction by spotting 20 μl of the reaction mixture onto an individually precut strip of phosphocellulose P81 paper.
- 8. Air dry the precut P81 strip and sequentially wash in the 1% phosphoric acid solution with constant gentle stirring. It is recommended the strips be washed a total of 3 times of ~10 minutes each.
- 9. Set up a radioactive control to measure the total  $\gamma$ - $^{32}$ P-ATP counts introduced into the reaction. Spot 5  $\mu$ l of the  $\gamma$ - $^{32}$ P-ATP Assay Cocktail on a precut P81 strip. Dry the sample for 2 minutes and read the counts. Do not wash this sample.
- Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
- 11. Determine the corrected cpm by subtracting the blank control value (see step 3) from each sample and calculate the kinase specific activity

#### Calculations:

1. Specific Radioactivity (SR) of ATP (cpm/nmole)

SR =  $\frac{\text{cpm of 5} \mu \text{l of } \gamma^{-32}\text{P-ATP Assay Cocktail}}{\text{nmole of ATP}}$ 

cpm – value from control (step 7) nmole – 1.25 nmole (5  $\mu$ l of 250  $\mu$ M ATP Assay Cocktail)

2. Specific Kinase Activity (SA) (nmole/min/mg)

nmole/min/mg = 
$$\Delta$$
cpm × (25/20)  
SR × F × T

SR = specific radioactivity of the ATP (cpm/nmole ATP) ∆cpm = cpm of the sample – cpm of the blank (step 3) 25 = total reaction volume

20 = spot volume

T = reaction time (minutes)

E = amount of enzyme (mg)

#### References

- Rapp, U. et al., Proc. Nat. Acad. Sci., 80, 4218-4222 (1983).
- 2. Li, P. et al., Cell, **64**, 479-482 (1991).

BKR,MAM 02/09-1